Literature DB >> 29628687

Megaprosthesis versus Allograft Prosthesis Composite for massive skeletal defects.

Deepak Gautam1, Rajesh Malhotra1.   

Abstract

Massive skeletal defects are encountered in the setting of tumors necessitating excision, failed total hip arthroplasty with periprosthetic bone loss, periprosthetic fracture, complex trauma, multiple failed osteosynthesis and infection. Reconstruction of the segmental defects poses a tremendous challenge to the orthopaedic surgeons. The goal of osseous reconstruction of these defects is to restore the bone length and function. Currently the most commonly employed methods for reconstruction are either a megaprosthesis or an Allograft Prosthesis Composite (APC). Megaprosthesis, initially created for the treatment in neoplastic pathologies are being used for the non-neoplastic pathologies as well. The longevity of these implants is an issue as majority of the patients receiving them are the survivors of oncologic issue or elderly population, both in which the life expectancy is limited. However, the early complications like instability, infection, prosthetic breakage and fixation failure have been extensively reported in several literatures. Moreover, the megaprostheses are non-biological options preventing secure fixation of the soft tissue around the implant. The Allograft Prosthesis Composites were introduced to overcome the complications of megaprosthesis. APC is made of a revision-type prosthesis cemented into the skeletal allograft to which the remaining soft tissue sleeve can be biologically fixed. APCs are preferred in young and low risk patients. Though the incidence of instability is relatively low with the composites as compared to the megaprosthesis, apart from infection, the newer complications pertaining to APCs are inevitable that includes non-union, allograft resorption, periprosthetic fracture and potential risk of disease transmission. The current review aims to give an overview on the treatment outcomes, complications and survival of both the megaprostheses and APCs at different anatomic sites in both the upper and lower limbs.

Entities:  

Keywords:  Allograft prosthetic composite; Bone tumors; Complex trauma; Failed total hip arthroplasty; Massive skeletal defect; Megaprosthesis

Year:  2017        PMID: 29628687      PMCID: PMC5884048          DOI: 10.1016/j.jcot.2017.09.010

Source DB:  PubMed          Journal:  J Clin Orthop Trauma        ISSN: 0976-5662


  124 in total

1.  [Proximal femoral reconstruction with megaprosthesis versus allograft prosthesis composite. A comparative study of functional results, complications and longevity in 41 cases].

Authors:  P Anract; J Coste; L Vastel; C Jeanrot; E Mascard; B Tomeno
Journal:  Rev Chir Orthop Reparatrice Appar Mot       Date:  2000-05

2.  Custom-made prosthesis replacement for reconstruction of elbow after tumor resection.

Authors:  Xiaodong Tang; Wei Guo; Rongli Yang; Shun Tang; Yi Yang
Journal:  J Shoulder Elbow Surg       Date:  2009-07-01       Impact factor: 3.019

3.  Are Complications Associated With the Repiphysis(®) Expandable Distal Femoral Prosthesis Acceptable for Its Continued Use?

Authors:  Eric L Staals; Marco Colangeli; Nikolin Ali; José M Casanova; Davide M Donati; Marco Manfrini
Journal:  Clin Orthop Relat Res       Date:  2015-05-21       Impact factor: 4.176

4.  Allograft-prosthesis composite reconstruction for the management of failed elbow replacement with massive structural bone loss: a medium-term follow-up.

Authors:  R Amirfeyz; D Stanley
Journal:  J Bone Joint Surg Br       Date:  2011-10

5.  Management of extensor mechanism deficit as a consequence of patellar tendon loss in total knee arthroplasty: a new surgical technique.

Authors:  Rajesh Malhotra; Bhavuk Garg; Vivek Logani; Surya Bhan
Journal:  J Arthroplasty       Date:  2008-01-24       Impact factor: 4.757

6.  Revision arthroplasty with use of a reverse shoulder prosthesis-allograft composite.

Authors:  Ariel Chacon; Nazeem Virani; Robert Shannon; Jonathan C Levy; Derek Pupello; Mark Frankle
Journal:  J Bone Joint Surg Am       Date:  2009-01       Impact factor: 5.284

7.  Allograft-prosthetic composite in the proximal tibia after bone tumor resection.

Authors:  Davide Donati; Marco Colangeli; Simone Colangeli; Claudia Di Bella; Mario Mercuri
Journal:  Clin Orthop Relat Res       Date:  2008-01-10       Impact factor: 4.176

8.  Pasteurized autograft-prosthesis composite for reconstruction of proximal tibia in 13 sarcoma patients.

Authors:  Dae-Geun Jeon; Min Suk Kim; Wan Hyeong Cho; Won Seok Song; Soo-Yong Lee
Journal:  J Surg Oncol       Date:  2007-12-01       Impact factor: 3.454

9.  Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli.

Authors:  Woo Kyung Jung; Hye Cheong Koo; Ki Woo Kim; Sook Shin; So Hyun Kim; Yong Ho Park
Journal:  Appl Environ Microbiol       Date:  2008-02-01       Impact factor: 4.792

10.  Distal femoral replacement with the MML system: a single center experience with an average follow-up of 86 months.

Authors:  Andreas Toepfer; Norbert Harrasser; Paul-Ruben Schwarz; Florian Pohlig; Ulrich Lenze; Heinrich M L Mühlhofer; Ludger Gerdesmeyer; Ruediger von Eisenhart-Rothe; Christian Suren
Journal:  BMC Musculoskelet Disord       Date:  2017-05-22       Impact factor: 2.362

View more
  13 in total

Review 1.  Imaging following surgery for primary appendicular bone tumours.

Authors:  Imran Khan; Craig Gerrand; Asif Saifuddin
Journal:  Skeletal Radiol       Date:  2021-01-22       Impact factor: 2.199

2.  Bone Allograft Prosthesis Composite to Revise a Failed Massive Allo-Prosthesis: Case Report and 10 Years of Follow-Up.

Authors:  Manuel R Medellin; Alejandro Abiad; Vanessa Salinas; Luis Carlos Gomez-Mier; Camilo Soto Montoya
Journal:  Cureus       Date:  2020-12-19

Review 3.  Megaprosthesis Versus Allograft Prosthesis Composite for the Management of Massive Skeletal Defects: A Meta-Analysis of Comparative Studies.

Authors:  Deepak Gautam; Nitish Arora; Saurabh Gupta; Jaiben George; Rajesh Malhotra
Journal:  Curr Rev Musculoskelet Med       Date:  2021-04-17

Review 4.  Reverse shoulder arthroplasty after failed megaprosthesis for osteosarcoma of the proximal humerus: A case report and review of literature.

Authors:  V Singh Chauhan; Abhishek Vaish; Raju Vaishya
Journal:  J Clin Orthop Trauma       Date:  2019-03-22

5.  What Is the Survival and Function of Modular Reverse Total Shoulder Prostheses in Patients Undergoing Tumor Resections in Whom an Innervated Deltoid Muscle Can Be Preserved?

Authors:  Giulia Trovarelli; Alessandro Cappellari; Andrea Angelini; Elisa Pala; Pietro Ruggieri
Journal:  Clin Orthop Relat Res       Date:  2019-11       Impact factor: 4.176

Review 6.  Current review of surgical management options for extremity bone sarcomas.

Authors:  Catalin Cirstoiu; Bogdan Cretu; Bogdan Serban; Zsombor Panti; Mihai Nica
Journal:  EFORT Open Rev       Date:  2019-05-10

7.  Clinical outcome of various limb salvage surgeries in osteosarcoma around knee: Megaprosthesis, extracorporeal irradiation and resection arthrodesis.

Authors:  Achmad Fauzi Kamal; Primadika Rubiansyah
Journal:  Ann Med Surg (Lond)       Date:  2019-04-24

8.  Complications following allograft reconstruction for primary bone tumors: Considerations for management.

Authors:  Joseph A Ippolito; Maximilian Martinez; Jennifer E Thomson; Alexander R Willis; Kathleen S Beebe; Francis R Patterson; Joseph Benevenia
Journal:  J Orthop       Date:  2018-12-20

9.  Comparative efficacy of intraoperative extracorporeal irradiated and alcohol-inactivated autograft reimplantation for the management of osteosarcomas-a multicentre retrospective study.

Authors:  Meitao Xu; Ming Xu; Shuai Zhang; Hanqing Li; A I Qiuchi; Xiuchun Yu; Xu Quan Wang
Journal:  World J Surg Oncol       Date:  2021-05-26       Impact factor: 2.754

10.  Using personalized 3D printed Titanium sleeve-prosthetic composite for reconstruction of severe segmental bone loss of proximal femur in revision total hip arthroplasty: A case report.

Authors:  Xingshan Wang; Hui Xu; Ji Zhang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.